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I  Introduction
Benzodiazepines have a range of clinical uses and are one 
of the most commonly prescribed medicines globally. They 
have proven useful in treating a range of health problems 
including anxiety, insomnia and alcohol withdrawal (Medicines 
and Healthcare Products Regulatory Agency, 2014). However, 
like all medicines, there can be side effects associated with 
benzodiazepine use, in particular with the misuse of these 
medicines, which for the purposes of this analysis we define 
as use without a prescription from a medical practitioner or 
with a prescription but outside of accepted medical practice 
or guidelines. 
While the misuse of benzodiazepines has been identified as 
a concern for a number of groups in the general population, 
e.g. among the elderly and women, this analysis focuses 
specifically on the misuse of benzodiazepines among high-
risk opioid users (1), a group where these medicines have been 
linked with severe treatment challenges and implicated in high 
levels of drug-related deaths.
It is important to stress that much benzodiazepine prescribing 
to high-risk drug users is for legitimate therapeutic purposes. 
Nevertheless, there are concerns relating to unintended health 
consequences associated with the use of benzodiazepine for 
longer periods (e.g. more than two to three weeks), polydrug 
use, and use that is not in accordance with prescribing 
guidelines.
Benzodiazepines are a widely prescribed 
group of medicines with a range of clinical 
uses, including the treatment of anxiety 
and insomnia and the management 
of alcohol withdrawal. For a number of 
reasons this group of medicines are often 
misused by high-risk opioid users and are 
associated with morbidity and mortality 
among this group. This analysis considers 
the significance of this problem and its 
impact for the health and drug treatment 
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(1) A definition of high-risk opioid users is available on the EMCDDA website (www.
emcdda.europa.eu/attachements.cfm/att_218205_EN_PDU%20revision.pdf).
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As we describe below, available evidence shows that the 
misuse of benzodiazepines contributes to morbidity and 
mortality among high-risk opioid users. This includes a greater 
risk of heroin overdose, as well as being associated with a 
higher risk of human immunodeficiency virus (HIV) infections, 
psychopathology (anxiety and depression), poorer treatment 
outcomes and poorer social functioning (Darke et al., 1995; 
Lader, 2012; Ford and Law, 2014).
I  Benzodiazepine misuse among high-risk opioid users  
High-risk opioid users typically misuse benzodiazepines to 
self-medicate or to increase the effects of opioids (Vogel et 
al., 2013). Users self-medicate to treat psychiatric disorders 
and negative emotional states (anxiety, insomnia) and to 
alleviate opiate withdrawal symptoms or the adverse effects 
of drugs like alcohol or cocaine. Benzodiazepines can also 
prolong the intensity and duration of the effect of opioids, 
especially when injected. Patients in opioid substitution 
treatment (OST) with methadone, for example, may misuse 
benzodiazepines to increase the effects of their opioid 
medication (Jones et al., 2012). Reports suggest this practice 
may be correlated with an under-dosing of the substitution 
treatment, which results in the re-emergence of withdrawal 
symptoms (Chen et al., 2011). 
Benzodiazepines are generally taken orally, snorted, and by 
intravenous injection among high-risk opioid users. While a 
wide variety of types of benzodiazepines are available and 
misused in Europe by high-risk opioid users, those most 
commonly reported in studies or identified in statistics of 
drug-related deaths are diazepam, clonazepam, alprazolam, 
oxazepam and flunitrazepam. Benzodiazepines with a 
more rapid onset of action (e.g. diazepam, alprazolam or 
lorazepam) appear to be more frequently used by opioid 
users than those with a slower onset (e.g. oxazolam or 
prazepam). 
Users obtain benzodiazepines from different sources, 
including diversion of prescriptions (such as ‘doctor 
shopping’ (2)), the illicit market and the Internet. A growing 
number of benzodiazepines that are not approved medicines 
within the European Union (EU), such as flubromazolam or 
flubromazepam, have been identified for sale at street level 
and online.
Figure 1. Substances reported as their secondary drug by 
clients entering drug treatment for primary opioid problems
While treatment demand data (3) do not allow us to gauge the 
full scale of benzodiazepine misuse, it does give an important 
insight into the scope of the problem. Data show that the 
combined use of opioids and benzodiazepines is a significant 
issue among those receiving treatment. Available data for 
2014 from 18 countries (4) where opioids were reported as 
the primary problem drug (5) by those entering treatment 
(102 000, or 19 % of all clients) show benzodiazepines were 
reported as a secondary problem drug (6) by 11 %, or 10 000 
of those entering treatment. Higher levels were reported in 
some countries, ranging from 30–50 % of those entering 
treatment. However, it should be noted that secondary drugs, 
including benzodiazepines, are often under-reported.
The prevalence of benzodiazepine misuse among clients 
in OST ranges from 45 % in France (Brisacier and Collin, 
2014) to 70 % in Germany (Specka et al., 2011; Laqueille et 
al., 2009). The frequency of benzodiazepine misuse among 
those undergoing OST is reported to increase with the 
length of treatment (Fernández Sobrino et al., 2009). This 
factor has also been identified in other treatment outcome 
studies (Comiskey, 2013; Stewart et al., 2002). High rates of 
benzodiazepine misuse have also been found among high-
(2) ‘Doctor shopping’ refers to the practice of a patient requesting care from multiple physicians, often simultaneously, without making efforts to coordinate care or informing 
the physicians of the multiple caregivers. This usually stems from a patient’s addiction to, or reliance on, certain prescription drugs or other medical treatment.
(3) European countries provide data according to the same protocol (treatment demand indicator standard protocol 3.0) on the characteristics and patterns of drug use of 
people entering drug treatment for problems related to their drug use (www.emcdda.europa.eu/publications/manuals/tdi-protocol-3.0). 
(4) Data from 18 of 30 countries: Belgium, Bulgaria, the Czech Republic, Ireland, Greece, Croatia, Italy, Cyprus, Malta, Netherlands, Austria, Portugal, Romania, Slovenia, 
Slovakia, Finland, the United Kingdom and Turkey. 
(5) The primary drug is defined as the drug that causes the client the most problems at the start of treatment. This is usually based on the request made by the clients and/
or on the diagnosis made by a therapist, commonly using international standard instruments (e.g. ICD-10; DSM-IV; ASI) or clinical assessment. This item is of central impor-
tance and it should be collected for every client. Secondary drugs are those drugs used in addition to the primary drug, and are substances that cause problems for the client 
and/or change the nature of the problem as assessed by the client and the therapist (www.emcdda.europa.eu/publications/manuals/tdi-protocol-3.0).
(6) A secondary drug should be recorded ‘only if it causes problems to the client according to the client’s request and to the professional’s assessment’ (TDI version 3.0).
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risk opioid users in prisons, with one study involving 38 Italian 
prisons finding that 85 % of opioid users were misusing 
benzodiazepines (Nava, 2014). Current data on trends in 
benzodiazepine misuse among high-risk opioid users in 
treatment indicate a relatively stable trend between 2006 and 
2013, with a decrease in the last year.
The majority of reported benzodiazepine misuse occurs 
among those reporting opioid use as the primary drug for 
which they are entering treatment. However, around 7 000, or 
2 % (range: 0–20 %), of all clients entering treatment reported 
benzodiazepines as the primary drug of misuse; and 20 % of 
these clients also reported the use of opioids as a secondary 
drug. Ireland, Finland and Romania are the countries with 
the highest rates, where more than 5 % of treatment clients 
reported benzodiazepine use as their primary drug problem. 
I  Health harms
There is evidence of various harms associated with 
benzodiazepine misuse among both the general population 
and in particular vulnerable groups including high-risk opioid 
users. This can include problems associated with rapid 
tolerance, dependence and withdrawal. In the latter case 
this can include increased anxiety, agitation, confusion and 
panic attacks, and can lead, in vulnerable people, to acute 
psychosis. Abrupt withdrawal can cause uncontrollable and 
potentially fatal convulsions (Jones et al., 2012; Ashton, 
1986). The cessation of benzodiazepine use is complex and 
requires medical support, which can include the use of other 
medications to manage withdrawal or provide substitution. 
Sometimes this process might need to take place in an 
inpatient setting.
The use of benzodiazepines has been linked with long-term 
effects including over-sedation, depression and immune 
system problems. As side effects can be more pronounced 
in the elderly, Europe’s ageing population of chronic opioid 
users are at extra risk. Polydrug use involving opioids 
and benzodiazepines can also expose users to other risk 
behaviours and drug-related harms. These include needle-
sharing, using higher doses of drugs, intoxication-related 
accidents, and poor physical and psychological health (Vogel 
et al., 2013; Lavie et al., 2009; Rooney et al., 1999).
Studies suggest that opioid users who use/misuse 
benzodiazepines experience a high level of health problems 
and use health services frequently. For example, the 
Australian Treatment Outcome Study (ATOS) (Darke et al., 
2003) looked at the relationship between use of healthcare 
services and benzodiazepine misuse among heroin users. 
It found that heroin users who also used benzodiazepines 
had frequent general practitioner (GP) and psychiatrist visits, 
were more likely to have had an ambulance attendance 
and had significantly more dispensed prescriptions 
than other heroin users. A recent study in France among 
patients on buprenorphine explored the co-prescription of 
benzodiazepines on opioid treatment outcomes; although 
no impact on outcome was identified, benzodiazepine 
prescription was associated with more frequent emergency 
department visits and accidental injuries (Schuman-Olivier et 
al., 2013).
Video on misuse of benzodiazepines among high-risk opioid users, available on the 
EMCDDA website: www.emcdda.europa.eu/topics/pods/benzodiazepines
I  Interactive element: video
I  Facts and figures 
Benzodiazepines were introduced into clinical medicine 
in the early 1960s. They rapidly replaced barbiturates as 
sedative-hypnotics because they were safer, particularly 
because they were less likely to cause fatal central nervous 
system depression (Longo and Johnson, 2000; EMCDDA 
drug profile). 
Benzodiazepines act as central nervous system depressants 
by enhancing the actions of the neurotransmitter GABA 
(gamma-aminobutyric acid). This has a calming effect on 
many functions of the brain, including inducing sedation and 
sleep (Lalive et al., 2011). 
They are used for treating psychiatric and neurological 
conditions, including insomnia, anxiety disorders, alcohol 
dependence and epilepsy. Some are also used as a pre-
anaesthetic and intraoperative medication (Medicines and 
Healthcare Products Regulatory Agency, 2014).
Benzodiazepines can be divided into different groups based 
on their chemical structure and pharmacokinetic properties, 
although they share a common mechanism of action and 
produce similar pharmacological effects (Baldwin et al., 
2013).
Based on their pharmacokinetics, benzodiazepines can 
be placed into one of three groups. These are: short-acting 
agents, with half-lives of under six hours (e.g. oxazepam), 
intermediate-acting agents with half-lives of 6–24 hours 
(alprazolam), and long-acting agents with half-lives of over 
24 hours (diazepam) (Medicines and Healthcare Products 
Regulatory Agency, 2014).




Simultaneous use of opioids with benzodiazepines and 
other central nervous system depressants, such as alcohol, 
increases the risk of non-fatal and fatal overdose through 
respiratory depression (White and Irvine, 1999). 
The increased risk of overdose among opioid users is 
reflected in the high frequency of benzodiazepines identified 
in post-mortem examinations of drug-related death cases. 
For example, benzodiazepines were identified in 40–80 % of 
methadone-related deaths (France, United States, Australia) 
and in 50–80 % of heroin-related deaths (Germany, Ireland, 
United Kingdom) (Lintzeris et al., 2007). Current European 
Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 
drug-induced deaths data show that benzodiazepines were 
implicated (i.e. they were thought to have played a role in 
the death) in 28 % of deaths in Scotland (7), 48 % in France, 
30–32.5 % in Portugal (8) and 35 % in Ireland (9). In addition, 
when the presence of benzodiazepines is considered in 
drug-induced deaths, percentages have been reported for 
Scotland (72 %) (10) and Finland (88 %) (11). It is, however, 
important to note that that even when benzodiazepines were 
not implicated in deaths, they may have played a role in risk 
behaviours that led to death. 
Insights from hospital emergency departments
Data from hospital emergency departments provide valuable 
insights into drug user and related health problems. This 
information can be used as a leading edge or real time indicator of 
drug problems. The European Drug Emergencies Network  
(Euro-DEN) project is a European Commission Drug Prevention and 
Information Programme funded project that involves longitudinal 
collection of data from 16 sentinel centres in 10 European countries 
on emergency department presentations with acute drug and NPS 
toxicity (Wood et al., 2014). 
The Euro-DEN database was searched to identify cases from  
1 October 2013 to 30 June 2014 where heroin had been used prior 
to presentation. Of the 3 573 Euro-DEN cases over this nine-month 
period, 872 (23.2 %) involved self-reported use of heroin. Of these, 
221 (25.3 %) had also used one or more benzodiazepines (of which 
196 (88.7 %) involved one benzodiazepine, 21 (9.5 %) involved two 
benzodiazepines and 3 (1.8 %) involved three benzodiazepines) 
(Dargan et al., 2015). 
There was significant variation across the Euro-DEN centres, ranging 
from no heroin presentations in Barcelona, Copenhagen and Paris 
involving a benzodiazepine to 35.6 % of heroin presentations in 
Oslo involving a benzodiazepine. There was no significant difference 
in the age or gender of the heroin–benzodiazepine cases and 
the heroin cases not involving a benzodiazepine, and there was 
no difference in the proportion with coma. However, those in the 
heroin–benzodiazepine group had a longer stay in hospital (5 hours  
46 minutes versus 4 hours 45 minutes, p=0.03) and were more  
likely to be admitted to critical care.
There have been case reports of fatal poisonings involving 
mixing benzodiazepines with buprenorphine in France, where 
buprenorphine is more commonly used than methadone 
for substitution treatment, with benzodiazepines identified 
in 70 % of buprenorphine-related deaths (France, special 
mortality register data, DRAMES 2012; Reynaud et al., 1998). 
While buprenorphine causes less respiratory depression 
than methadone, non-clinical studies have found that its 
ceiling effect on respiratory depression is removed when 
combined with benzodiazepines (Nielsen and Taylor, 2005). 
For all opioids, establishing the role of benzodiazepines in 
drug-related deaths is complicated by several factors. For 
instance, the combinations of drugs identified are often 
complex, individuals have different levels of tolerance and 
metabolisms, and a level of subjectivity exists in toxicological 
assessments.
(7) ‘Drug-related deaths in Scotland 2013’, published by National Records Scotland (www.nrscotland.gov.uk/statistics-and-data/statistics/statistics-by-theme/vital-events/
deaths/drug-related-deaths-in-scotland/2013).
(8) Two data sources have been used to illustrate the situation in Portugal, the Special Mortality Register and the General Mortality Register. 
(9) As was illustrated by recent data from a number of countries during the latest annual drug-related deaths experts’ meeting (www.emcdda.europa.eu/expert-meet-
ings/2014/drd-drid). 
(10) ‘Drug-related deaths in Scotland 2013’, published by National Records Scotland (www.nrscotland.gov.uk/statistics-and-data/statistics/statistics-by-theme/vital-events/
deaths/drug-related-deaths-in-scotland/2013).
(11) See note 10.
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I  Challenges for the future
Benzodiazepines have a range of well-established clinical 
uses and side effects. This makes their widespread availability 
and the potential for misuse a serious problem, particularly 
where they are taken by opioid users as part of polydrug use 
repertoires. The picture that emerges from research studies 
and the available epidemiological data presents a challenging 
situation. Benzodiazepines have a role in the management of 
the mental health issues opioid users experience from their 
drug consumption. However, the misuse of benzodiazepines 
with other drugs can expose users to a spectrum of 
problems ranging from mental health issues, compromised 
treatment outcomes and risky drug consumption practices, 
to more severe consequences such as non-fatal and fatal 
overdoses. To date, however, benzodiazepine misuse 
alongside other drugs among high-risk opioid users has 
often been viewed by users and service providers as a 
secondary issue, neglecting its polydrug use dimension and 
consequences. The situation is further complicated by the 
emergence of new benzodiazepines on the illicit market in 
some countries, for example, phenazepam and etizolam, 
which have been implicated in several deaths among 
opioid users in Scotland (12). With a continuing need to use 
benzodiazepines for various medical purposes and in order 
tomitigate the risks opioid users taking them face, prescribing 
and clinical practice guidelines have a critical role to play in 
the management of this issue as part of a comprehensive 
response to polydrug users among high-risk opioid drug 
users. Giving the ageing nature of this population within 
Europe and the increased potential for health complications 
from ongoing drug use, this issue is an existing challenge that 
treatment systems must address.
There are only a few evidence-based clinical guidelines 
available to support practitioners on the use and 
management of benzodiazepines among high-risk opioid 
users. The EMCDDA’s Best Practice Inventory  
(www.emcdda.europa.eu/best-practice) currently contains 
six sets of guidelines that address these issues, as part of 
general or specific guidelines for managing opioid use. 
 
The Substance Misuse Management in General 
Practice guidance in the United Kingdom, which 
specifically addresses the use and reduction of misuse 
of benzodiazepines and other hypnotics and anxiolytics, 
proposes a strategic course of action: 
 
Strategy for prescribing benzodiazepines to opioid-
dependent patients: 
 
1. Treat the opioid dependence first; this has a good 
evidence base. 
 
2. Discuss with patients how they will control and reduce 
their benzodiazepine use themselves (without the need for 
a benzodiazepine prescription). Many patients are able to 
reduce their illicit supply themselves. 
 
3. Re-assess patients’ benzodiazepine use once they 
are stable on their opioid prescription and it has been 
optimised. Clinical experience shows that benzodiazepine 
use (even what clinically appears to be dependence) often 















4. If use of benzodiazepines is continuing, reassess 
the reasons. Is it for sedation, the ‘buzz’, anxiety or the 
comedown from crack or other drugs? Does it enhance the 
opioid ‘buzz’? Do not prescribe benzodiazepines if use is for 
pleasure or in binges. 
 
5. If dependence on benzodiazepines is present, consider a 
short term (six weeks to six months) reducing prescription 
of benzodiazepines on daily pickup (a minimum of six days 
a week). 
 
6. Stop the benzodiazepine prescription if persistent illegal 
benzodiazepine use or alcohol dependence are present. 
 
7. Consider similar staged detoxification as with other 
patients dependent on benzodiazepines. 
Guidelines for prescribing benzodiazepines to opioid users  
(12) Most drug-induced deaths in Scotland involving benzodiazepines were linked to diazepam, but phenazepam, which was placed under control in the United Kingdom in 
2012, and etizolam, which is not controlled, were also implicated in several deaths.
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